<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04168671</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/886/2018</org_study_id>
    <nct_id>NCT04168671</nct_id>
  </id_info>
  <brief_title>CLE During Exercise Testing in Asthma</brief_title>
  <acronym>CLEtesting</acronym>
  <official_title>Continuous Laryngoscopy During Exercise Testing in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess visualize the level of laryngeal obstruction and vocal cord
      dysfunction and to obtain more information on causes for dyspnea in asthma and severe asthma
      and to assess safety of CLE in patients with asthma and with severe asthma. Patients are
      examined if symptomatic during exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Questionnaires to assess breathlessness before the test.

        -  CLE on ergometer bicycle using any laryngoscopy setup

        -  Ergometry with spirometry tests with ECG, oxygen saturation, blood pressure, inspiratory
           and expiratory flow volume curves, bronchodilator after the exercise test

        -  Work load of 40W with 3 minutes intervals and increase by 40W in women. In men, work
           load of 50W with 3 minutes intervals and increase by 50W starting from 50W. In elderly
           and more severely disease work load of 30W with 3 minutes intervals and increase by 30W.

        -  Recording of dyspnoea, leg fatigue and chest discomfort

        -  Assessment of asthma by asthma control test, spirometry, exhaled NO measurements.

        -  Severe asthma group: physician-diagnosed asthma, moderate-high dose inhaled glucorticoid
           steroids and a second controller drug, exacerbations and per oral glucocorticoid steroid
           courses at least 2 in the past 12 months and/or 50% of the past 12 months on per oral
           glucocorticoidsteroids
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Asthma vs severe asthma</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laryngeal obstruction</measure>
    <time_frame>From immediately before (-5 minutes) before the exercise test, during the test up to 30 minutes</time_frame>
    <description>Semi-quantitative visual estimation of laryngeal obstruction in test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of CLE in asthma (Incidence of test-emergent adverse events)</measure>
    <time_frame>From immediately before (-10 minutes) before the exercise test, during the test up to 30 minutes</time_frame>
    <description>Incidence of test-emergent adverse events: nasal bleeding or pain, panic attack, bronchial obstruction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity in CLE in asthma</measure>
    <time_frame>From 0 minutes before the exercise test and during the test up to 30 minutes</time_frame>
    <description>Maximal work load in exercise test measured by W max 4 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea in CLE in asthma</measure>
    <time_frame>From 0 minutes before the exercise test and during the test up to 30 minutes</time_frame>
    <description>Assessment of patient reported dyspnea in maximal exercise measured by scale from 0 to 10 (Borg's scale) (0 no symptoms - 10 maximal dyspnea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise induced lung function changes</measure>
    <time_frame>Immediately before test (0 minutes), and 10 minutes and 20 minutes after the test</time_frame>
    <description>Change from baseline FEV1 after the test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Larynx</condition>
  <condition>Obstruction</condition>
  <condition>Vocal Cord Dysfunction</condition>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Asthma and symptomatic during exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Severe asthma and symptomatic during exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Continuous laryngoscopy during exercise test</intervention_name>
    <description>Continuous laryngoscopy during exercise test</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Severe asthma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  physician diagnosed asthma

          -  symptomatic during exercise

        Exclusion Criteria:

          -  FEV1 &lt;60%

          -  respiratory infection in the last 14 days

          -  asthma excacerbation in the last 14 days

          -  unstable cardiovascular disease

          -  bleeding disorder

          -  anticoagulant treatment (other than ASA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Kauppi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Kauppi, MD, PhD</last_name>
    <phone>+358504286802</phone>
    <email>paula.kauppi@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mika M채kel채, Professor</last_name>
    <email>mika.makela@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula M Kauppi</last_name>
      <email>paula.kauppi@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Mika J M채kel채</last_name>
      <email>mika.makela@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Lawlor C, Smithers CJ, Hamilton T, Baird C, Rahbar R, Choi S, Jennings R. Innovative management of severe tracheobronchomalacia using anterior and posterior tracheobronchopexy. Laryngoscope. 2020 Feb;130(2):E65-E74. doi: 10.1002/lary.27938. Epub 2019 Mar 25.</citation>
    <PMID>30908672</PMID>
  </reference>
  <reference>
    <citation>Bardin PG, Low K, Ruane L, Lau KK. Controversies and conundrums in vocal cord dysfunction. Lancet Respir Med. 2017 Jul;5(7):546-548. doi: 10.1016/S2213-2600(17)30221-7.</citation>
    <PMID>28664856</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Paula Kauppi, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD, Chief Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vocal Cord Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

